UroGen Pharma (NASDAQ:URGN) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research note published on Tuesday morning, Benzinga reports. They currently have a $60.00 target price on the stock.

A number of other brokerages have also recently commented on URGN. Guggenheim started coverage on UroGen Pharma in a research report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price target on the stock. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $48.38.

UroGen Pharma Stock Up 1.9 %

Shares of URGN opened at $12.84 on Tuesday. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23. UroGen Pharma has a 12 month low of $10.60 and a 12 month high of $20.70. The firm’s 50 day moving average is $13.48 and its 200-day moving average is $14.36. The stock has a market capitalization of $301.15 million, a PE ratio of -3.78 and a beta of 1.11.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The company had revenue of $21.85 million during the quarter, compared to analyst estimates of $23.69 million. Equities research analysts forecast that UroGen Pharma will post -3.49 EPS for the current year.

Institutional Trading of UroGen Pharma

Several large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its stake in UroGen Pharma by 65.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,903 shares of the company’s stock valued at $89,000 after purchasing an additional 2,328 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of UroGen Pharma during the third quarter worth $179,000. ProShare Advisors LLC bought a new position in shares of UroGen Pharma in the 2nd quarter valued at $199,000. Main Street Financial Solutions LLC bought a new position in shares of UroGen Pharma in the 2nd quarter valued at $403,000. Finally, Tidal Investments LLC acquired a new stake in shares of UroGen Pharma during the 1st quarter valued at $425,000. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.